Evidence map›Paper›PMID 23903654›Full record

ArticleNature2013

The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein.

Tiziana Sonati, Regina R Reimann, Jeppe Falsig, Pravas Kumar Baral, Tracy O'Connor, Simone Hornemann, Sine Yaganoglu, Bei Li, Uli S Herrmann, Barbara Wieland and 8 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
127citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

127 citing papers in PubMed, 1 synthesis or guideline pooled it, 206 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Creutzfeldt-Jakob disease and other prion diseases.Nature reviews. Disease primers · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Diminished Neuronal ESCRT-0 Function Exacerbates AMPA Receptor Derangement and Accelerates Prion-Induced Neurodegeneration.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  19. Mechanisms of prion-induced toxicity.Cell and tissue research · 2023
    Review
  20. Vaccines for prion diseases: a realistic goal?Cell and tissue research · 2023
    Review

67 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Tiziana SonatiInstitute of Neuropathology, University Hospital Zurich, Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland.
Regina R Reimann
Jeppe Falsig
Pravas Kumar Baral
Tracy O'Connor
Simone Hornemann
Sine Yaganoglu
Bei Li
Uli S Herrmann
Barbara Wieland
Mridula Swayampakula
Muhammad Hafizur Rahman
Dipankar Das
Nat Kav
Roland Riek
Pawel P Liberski
Michael N G James
Adriano Aguzzi
University Hospital of Zurich · CHUniversity of Alberta · CAETH Zurich · CHMedical University of Lodz · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prion infections cause lethal neurodegeneration. This process requires the cellular prion protein (PrP(C); ref. 1), which contains a globular domain hinged to a long amino-proximal flexible tail. Here we describe rapid neurotoxicity in mice and cerebellar organotypic cultured slices exposed to ligands targeting the α1 and α3 helices of the PrP(C) globular domain. Ligands included seven distinct monoclonal antibodies, monovalent Fab1 fragments and recombinant single-chain variable fragment miniantibodies. Similar to prion infections, the toxicity of globular domain ligands required neuronal PrP(C), was exacerbated by PrP(C) overexpression, was associated with calpain activation and was antagonized by calpain inhibitors. Neurodegeneration was accompanied by a burst of reactive oxygen species, and was suppressed by antioxidants. Furthermore, genetic ablation of the superoxide-producing enzyme NOX2 (also known as CYBB) protected mice from globular domain ligand toxicity. We also found that neurotoxicity was prevented by deletions of the octapeptide repeats within the flexible tail. These deletions did not appreciably compromise globular domain antibody binding, suggesting that the flexible tail is required to transmit toxic signals that originate from the globular domain and trigger oxidative stress and calpain activation. Supporting this view, various octapeptide ligands were not only innocuous to both cerebellar organotypic cultured slices and mice, but also prevented the toxicity of globular domain ligands while not interfering with their binding. We conclude that PrP(C) consists of two functionally distinct modules, with the globular domain and the flexible tail exerting regulatory and executive functions, respectively. Octapeptide ligands also prolonged the life of mice expressing the toxic PrP(C) mutant, PrP(Δ94-134), indicating that the flexible tail mediates toxicity in two distinct PrP(C)-related conditions. Flexible tail-mediated toxicity may conceivably play a role in further prion pathologies, such as familial Creutzfeldt-Jakob disease in humans bearing supernumerary octapeptides.

Indexed as

PliabilityAmino Acid SequenceAnimalsAntibodiesAntibodies, MonoclonalBinding Sites, AntibodyCalpainCerebellumCreutzfeldt-Jakob SyndromeCross-Linking ReagentsEpitope MappingFemaleImmunoglobulin Fab FragmentsIn Vitro TechniquesLigandsMaleAntibodiesAntibodies, MonoclonalCalpainCross-Linking ReagentsCybb protein, mouseImmunoglobulin Fab FragmentsLigandsMembrane GlycoproteinsNADPH Oxidase 2NADPH OxidasesPrionsPrPC ProteinsReactive Oxygen SpeciesSingle-Chain Antibodies

Identifiers

PMID23903654
OpenAlexW2070989278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.